Skip to content

    Privi Speciality Chemicals Q1 FY27 earnings call

    PRIVISCL
    Chemicals·31 Jul 2026
    Management Summary

    Privi Speciality Chemicals Limited reported a strong Q1 FY27 with consolidated total income growing 20.01% YoY to ₹681.42 crores and PAT increasing to ₹83.2 crores. EBITDA margins remained robust at 24.58%, with management expecting them to sustain around 25%. The company is progressing with its capacity expansion plans, with Phase-1 commercialization imminent, and has filed the merger scheme with NCLT, targeting completion within FY27.

    Highlights

    6

    • Consolidated total income grew 20.01% YoY to ₹681.42 crores (Narayan S. Iyer, page 5).

    • PAT increased to ₹83.2 crores from ₹61.46 crores in Q1 FY26 (Narayan S. Iyer, page 5).

    • EBITDA margins at 24.58% for Q1 FY27, expected to sustain at ~25% (Narayan S. Iyer, page 5, Sanjeev Patil, page 7).

    • Working capital cycle improved to 108 days from 141 days (Narayan S. Iyer, page 6).

    • Phase-1 capacity expansion from 48,000 to 54,000 metric tons expected to commercialize shortly (Narayan S. Iyer, page 5, Sanjeev Patil, page 7).

    • Merger scheme filed with NCLT, expected to complete in FY27 (Narayan S. Iyer, page 5).

    Concerns

    1

    • Gross margin compressed by 650 basis points YoY, from 51% in Q1 FY26 to 44.2% in Q1 FY27 (Vivek Rakholiya, page 6).

    Key financials

    Single quarter

    09 metrics
    1. 01Total Income (Consolidated)₹681.42 Cr+20.0%YoY
    2. 02EBITDA₹167.47 Cr+18.7%YoY
    3. 03EBITDA Margin24.6%
    4. 04PAT₹83.2 Cr+35.4%YoY
    5. 05Net Debt₹865 Cr

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    ₹850 crores

    primarily internal accruals, with borrowing from banks or institutions if needed

    Debt

    Net ₹865 crores · 1.3x EBITDA

    M&A

    Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited

    merger · pending regulatory

    M&A

    PRIGIV Joint Venture

    joint venture · integrated · Consideration ₹NaN (other)

    Liquidity

    Liquidity disclosed

    Strong balance sheet, robust cash flows and disciplined capital allocation strategy position us well to capitalize on emerging opportunities while navigating external uncertainties.

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue
    Revenue
    ₹5,000 crores
    		High
    Profitability
    EBITDA
    ₹1,000 crores plus
    		High
    Margin
    EBITDA Margin
    similar to 24.6-25%
    		High
    Capacity
    Production Capacity (Phase-1)
    54,000 metric tons
    		High
    Capacity
    Production Capacity (Phase-2)
    66,000 metric tons
    		High
    New Products
    Advanced Specialty Products
    10
    		Medium
    Merger
    Merger Completion
    Completed
    		High
    Capex
    Total CAPEX
    ₹850-900 crores
    		High

    What to watch in Q2 FY27

    5

    Phase-1 Capacity Commercialization

    next quarter
    CurrentProgressing as planned, expected shortly
    TargetCommercial operations of 54,000 MT capacity

    Why it matters

    Key step in capacity expansion, directly impacts volume growth and revenue potential.

    current flagship product expansion will happen in the course of the next 15 days or so. So from 48,000 metric tons, as Narayan said in his opening remarks, from 48,000 metric tons we will go to 54,000 metric tons.

    Risks & concerns

    3
    RiskSeverity

    Gross Margin Compression

    Gross margin declined by 650 bps YoY in Q1 FY27, attributed to raw material mix and prior year's low-cost advantage. — Analyst acknowledged

    medium

    Raw Material Price Volatility

    Input costs remain volatile, but managed through operational efficiencies, cost optimization, and back-to-back contracts. — Management acknowledged

    medium

    Global Geopolitical Environment (Red Sea, Iran War)

    No significant impact on RM consumption, freight costs, or margins due to diversified sourcing and non-crude focus. — Management downplayed

    low

    Q&A highlights

    8

    “My first question was, so our gross margin came in at 44.2% in Q1 FY27 versus almost 51% in last year Q1 FY26, which is a decline of about 650 basis points, even as the revenue grew by 20%. What drove the compression and how much of it do you expect to recover over the balance of FY27?”

    Analyst questioned the significant YoY decline in gross margins, which management attributed to raw material mix and prior year's low-cost advantage, but assured EBITDA margins would sustain.

    asked by Vivek Rakholiya

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Performance and Growth Drivers

    Privi Speciality Chemicals reported a robust start to FY27, with consolidated total income reaching ₹681.42 crores, marking a 20.01% year-on-year growth. Profit after tax for the quarter stood at ₹83.2 crores, up from ₹61.46 crores in Q1 FY26. This performance was driven by healthy demand across both domestic and international markets, supported by volume growth, price increases, and an improved product mix.

    02

    EBITDA Margin Resilience and Outlook

    The company achieved an EBITDA of ₹167.47 crores, an 18.73% year-on-year growth, with EBITDA margins at 24.58% for Q1 FY27. Despite a 650 basis point compression in gross margins (from 51% to 44.2% YoY), management expressed confidence in sustaining EBITDA margins at around 24.6-25% in the near future. This resilience is attributed to operational efficiencies, cost optimization initiatives, and improved capacity utilization, which helped offset volatile input costs.

    03

    Capacity Expansion and Long-Term Vision

    Privi is actively executing its expansion roadmap, with Phase-1 capacity expansion, increasing production from 48,000 to 54,000 metric tons, expected to commercialize shortly (within 15 days of the call). Phase-2, which will further increase capacity to 66,000 metric tons, is targeted for completion by September 2027. The company reiterated its long-term vision to achieve ₹5,000 crores in revenue and over ₹1,000 crores in EBITDA within the next three to four years, representing a 2x growth.

    04

    Strategic Merger and Joint Venture Progress

    The proposed merger of Privi Speciality Chemicals Limited, Privi Fine Sciences Private Limited, and Privi Biotechnologies Private Limited is progressing well, with the scheme filed with NCLT and expected to complete within FY27. The PRIGIV joint venture achieved profitability in Q4 FY26, contributed ₹18 crores in revenue with a 14-15% EBITDA margin in Q1 FY27, and has seen an additional ₹50 crore equity investment for its next phase of expansion, indicating continued confidence in its growth trajectory.

    05

    New Product Pipeline and Bio-based Initiatives

    The company's product development pipeline is advancing, focusing on high-value specialty molecules like Maltol, Ethyl Maltol, Musk T, and Cyclopentanone. The long-term roadmap includes introducing 10 advanced specialty products as part of Phase-2 and Phase-3 expansion. A demonstration plant for bio-based products, handling 2 tons of biomass per day, is being set up in Navi Mumbai, with plans to run it for a year to study manufacturing nuances before scaling up, an initiative considered beyond the current ₹5,000 crore revenue roadmap.

    06

    Prudent Capital Structure and Funding Strategy

    As of June 2026, the company's net debt stood at ₹865 crores, with a net debt-to-EBITDA ratio of 1.29 and a net debt-to-equity ratio of 0.57x, reflecting a healthy financial position. ROE and ROCE for the quarter were 21.7% and 22.72% respectively. The planned CAPEX of ₹850-900 crores for the current and next two financial years will primarily be funded through internal accruals, with potential borrowing from banks or institutions as needed, while maintaining prudent financial ratios.

    This is an AI-generated summary of a publicly available earnings call transcript.